Every one of those 1 sits in a single category, fda-approval. American Medical Association is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 8 original sources each. Endocrine Society appears in 1 tracked Biotech story from June 12, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Endocrine Society
Every one of those 1 sits in a single category, fda-approval. American Medical Association is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 8 original sources each. Endocrine Society appears in 1 tracked Biotech story from June 12, 2026.
Stories tracked
1
Sources per story
8
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Endocrine Society. Shared-story counts are live from our verified record — not editorial picks.
Biopharma companies face a potentially shrinking market and tougher FDA standards after Senate testimony highlighted 'very low certainty evidence' for pediatric gender treatments. With systematic reviews failing to show robust benefit, pipeline programs and commercial prospects for puberty blockers and cross-sex hormones are at risk.